Skip to main content
SpringerLink
Log in

Management of proliferative diabetic retinopathy

  • Chapter
  • First Online:
Managing Diabetic Eye Disease in Clinical Practice

  • 960 Accesses

Abstract

Advancement from nonproliferative diabetic retinopathy (NPDR) into the proliferative stage is defined by the presence of neovascularization, or new blood vessel growth. Although neovascularization would seemingly be a helpful adaptation, ocular neovascularization is uniformly destructive and associated with a poor visual prognosis when unchecked.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med. 1994;331:1480-1487.

    Google Scholar 

  2. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88:583-600.

    Google Scholar 

  3. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-564.

    Google Scholar 

  4. Bandello F, et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013;50:1-20.

    Google Scholar 

  5. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.

    Google Scholar 

  6. Davis MD, Blodi BA. Proliferative diabetic retinopathy. In: Ryan SJ, Schachat AP, eds. Retina. Vol 2, 4th edn. St Louis, MO: Mosby;2006:1285-1322

    Google Scholar 

  7. Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1776.

    Google Scholar 

  8. American Academy of Opthalmology Retinal Panel. Preferred Practice Patterns – Diabetic Retinopathy. 2008. http://one.aao.org/summary-benchmark-detail/diabetic-retinopathysummary-benchmark–october-20. Accessed February 4, 2015.

  9. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381-389.

    Google Scholar 

  10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.

    Google Scholar 

  11. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.

    Google Scholar 

  12. Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992;99:1351-1357.

    Google Scholar 

  13. Bhavsar AR, Torres K, Glassman AR, Jampol LM, Kinyoun JL; Diabetic Retinopathy Clinical Research Network. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol. 2014;132:889-890.

    Google Scholar 

  14. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 suppl):766-785.

    Google Scholar 

  15. Weiter JJ, Zuckerman R. The influence of the photoreceptor-RPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation. Ophthalmology. 1980. 87:1133-1139.

    Google Scholar 

  16. Landers, M.B., 3rd, E. Stefansson, Wolbarsht ML. Panretinal photocoagulation and retinal oxygenation. Retina. 1982;2:167-175.

    Google Scholar 

  17. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet. 1998;351:28-31.

    Google Scholar 

  18. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.

    Google Scholar 

  19. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled trials. Lancet. 2008;372:1394-1402.

    Google Scholar 

  20. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385-1393.

    Google Scholar 

  21. Keech AC, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687-1697.

    Google Scholar 

  22. Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.

    Google Scholar 

  23. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62:3968-3975.

    Google Scholar 

  24. Diabetic Retinopathy Clinical Research; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.

    Google Scholar 

  25. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130:1145-1152.

    Google Scholar 

  26. Bressler SB,, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013;131:1033-1040.

    Google Scholar 

  27. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology. 1985;92:492-502.

    Google Scholar 

  28. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699-700.

    Google Scholar 

  29. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246:837-842.

    Google Scholar 

  30. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927-938.

    Google Scholar 

  31. Mason JO, 3rd. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina. 2008;28:1319-1324.

    Google Scholar 

  32. World Health Organization (WHO). Prevention of blindness from diabetes mellitus : report of a WHO consultation in Geneva, Switzerland, 9-11 November 2005. www.who.int/diabetes/publications/prevention_diabetes2006/en/. Accessed February 4, 2015.

Download references

Author information

Authors and Affiliations

  1. Emory Eye Center, Atlanta, GA, USA

    Andrew M. Hendrick

  2. School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

    Michael S. Ip

Authors
  1. Andrew M. Hendrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael S. Ip
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cole Eye Institute,Cleveland Clinic,Case Western Reserve University, Cleveland, Ohio, USA

    Rishi P Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hendrick, A.M., Ip, M.S. (2015). Management of proliferative diabetic retinopathy. In: Singh, R. (eds) Managing Diabetic Eye Disease in Clinical Practice. Adis, Cham. https://doi.org/10.1007/978-3-319-08329-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08329-2_9

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08328-5

  • Online ISBN: 978-3-319-08329-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation